Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

2.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.9K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
Autoimmune Disorders01:29

Autoimmune Disorders

2.0K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.0K
Antibody Actions01:26

Antibody Actions

3.3K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
3.3K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.8K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.8K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Integrated Neurological Change Score Is a Sensitive Neurological Composite Measure to Evaluate Cervical Spinal Cord Injury Trials.

Journal of neurotrauma·2026
Same author

Anti-Nogo-A NG101 treatment induces changes in spinal cord micro- and macrostructure following spinal cord injury.

Nature communications·2026
Same author

Use and reporting of systematic review methodology in EFSA scientific opinions on animal health and welfare.

Frontiers in veterinary science·2026
Same author

Enhanced clinical trial stratification in spinal cord injury: the value of electrophysiology.

Brain : a journal of neurology·2025
Same author

Cuneiform Nucleus Stimulation Can Assist Gait Training to Promote Locomotor Recovery in Individuals With Incomplete Tetraplegia.

Annals of neurology·2025
Same author

Preclinical Evidence of Nogo-A Inhibition in Stroke Recovery: A Scoping Review.

Stroke·2025

Related Experiment Video

Updated: Mar 8, 2026

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
10:19

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

Published on: November 23, 2013

16.8K

Nogo-A Antibodies for Progressive Multiple Sclerosis.

Benjamin V Ineichen1,2, Patricia S Plattner3,4, Nicolas Good3,4

  • 1Brain Research Institute, University of Zurich, Zurich, Switzerland. ineichen@protonmail.ch.

CNS Drugs
|January 21, 2017
PubMed
Summary

Neutralizing Nogo-A shows promise for repairing nerve damage and promoting myelin regrowth in multiple sclerosis (MS). Anti-Nogo-A antibodies demonstrate a good safety profile, offering potential new therapies for progressive MS.

More Related Videos

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K
Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies
10:47

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies

Published on: October 27, 2016

11.5K

Related Experiment Videos

Last Updated: Mar 8, 2026

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
10:19

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

Published on: November 23, 2013

16.8K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K
Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies
10:47

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies

Published on: October 27, 2016

11.5K

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Current multiple sclerosis (MS) therapies primarily address inflammation, with limited options for the progressive stage.
  • Progressive MS leads to increasing disability, necessitating treatments that promote neural repair and axonal regeneration.
  • Nogo-A, a neurite outgrowth inhibitor, is a potential therapeutic target for axonal and myelin repair in MS.

Purpose of the Study:

  • To review pre-clinical and clinical evidence for Nogo-A as a therapeutic target in MS.
  • To evaluate the potential of anti-Nogo-A antibodies for treating progressive multiple sclerosis.
  • To explore novel therapeutic strategies beyond anti-inflammatory approaches for MS.

Main Methods:

  • Review of pre-clinical studies on Nogo-A inhibition.
  • Analysis of clinical trial data (Phase I and II) for anti-Nogo-A antibodies and anti-LINGO-1 antibodies.
  • Examination of safety and efficacy data in various neurological conditions including MS, spinal cord injury, and amyotrophic lateral sclerosis (ALS).

Main Results:

  • Pre-clinical data support Nogo-A neutralization for axonal and myelin repair.
  • Anti-Nogo-A antibodies exhibit a favorable safety profile at high doses in clinical trials.
  • An antibody targeting LINGO-1 showed improved outcomes in acute optic neuritis.

Conclusions:

  • Nogo-A-suppressing antibodies represent promising drug candidates for both relapsing and progressive MS.
  • Targeting Nogo-A offers a potential therapeutic avenue for neuroprotection and repair in progressive MS.
  • Further investigation into Nogo-A antibodies is warranted for managing progressive MS disability.